ArticleCancer communications (London, England)2020

Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.

Yanli Hou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.